GSK's portfolio is uniquely exposed to two converging pressures: (1) a looming loss-of-exclusivity cliff across its crown-jewel HIV dolutegravir franchise (2027–2031), and (2) oncology assets challenged by the blood-brain barrier. A bioavailable oral formulation of elacridar — a potent dual P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) inhibitor — addresses both. Elacridar's prior clinical failure was driven purely by formulation inadequacy (poor oral bioavailability); a nanoparticle or lipid-based reformulation overcomes this. This report maps every major GSK/ViiV product against elacridar's mechanism, scores the combination opportunity, and identifies our lead programme.
Our lead recommendation is Niraparib (Zejula) + Elacridar for newly diagnosed glioblastoma (GBM) — a high-unmet-need indication where GSK is already running a Phase II trial with niraparib, and where elacridar co-administration is supported by compelling published pharmacology showing complete BBB transporter saturation and normalisation of brain exposure to knockout-mouse levels.
| Drug (Brand) | Class / Indication | 2024 Sales | LOE | P-gp / BCRP Substrate? | Combination Rationale | Opportunity Type | Score | Projected Combo Peak Sales |
|---|---|---|---|---|---|---|---|---|
| Dovato dolutegravir + lamivudine |
HIV-1 treatment (oral 2-drug) | £2,239m | 2031 | DTG: P-gp substrate (ABCB1, ABCG2 efflux at BBB). Efflux limits CNS reservoir penetration | Elacridar co-administration could enhance DTG penetration into CNS viral reservoirs, potentially addressing HIV-associated neurocognitive disorders (HAND) and advancing toward functional cure. Oral bioavailability of DTG already reasonable; the CNS reservoir opportunity is the key differentiator. Published data confirm P-gp efflux limits DTG brain concentrations | EFFICACY ↑ | MEDIUM | £2,600–3,000m (CNS/HAND line extension); scenario: 10–15% premium-priced segment |
| Triumeq DTG + abacavir + lamivudine |
HIV-1 treatment (3-drug STR) | ~£900m | 2029 | DTG: P-gp substrate. Abacavir: limited P-gp sensitivity. Combined CNS penetration sub-optimal | Same CNS reservoir rationale as Dovato, but Triumeq's LOE pressure is nearer and the product is in structural decline. Lower priority than Dovato | EFFICACY ↑ | LOW | £800–900m (modest uplift pre-LOE; limited runway) |
| Tivicay dolutegravir |
HIV-1 treatment (monotherapy backbone) | ~£1,100m | 2027–2028 | DTG: P-gp / BCRP substrate confirmed in vivo | LOE imminent; window for a CNS-enhancing combination would require fast development. The DTG compound patent expiry (2027) creates urgency; without a differentiation story, Tivicay is genericised. Elacridar combination could defend the premium brand in neurologically-at-risk HIV patients | EFFICACY ↑ | LOW | £500–700m (niche HAND indication; limited by LOE timing) |
| Cabenuva cabotegravir + rilpivirine LA injectable |
HIV-1 treatment (long-acting injectable) | ~£990m | ~2033+ | Rilpivirine: P-gp substrate. Cabotegravir: limited P-gp data. Injectable route bypasses oral bioavailability issue, but CNS penetration remains efflux-limited | Injectable route makes co-formulation with oral elacridar complex (different routes). Would require oral elacridar dosing before each injection to improve CNS penetration. Low practical utility for this rapidly-growing asset | N/A | LOW | No meaningful uplift; formulation incompatibility |
| Apretude cabotegravir LA injectable — PrEP |
HIV PrEP (prevention) | ~£270m | ~2033+ | Same injectable limitations as Cabenuva. PrEP context makes CNS enhancement less clinically relevant | No meaningful opportunity — PrEP patients are HIV-negative; CNS reservoir rationale does not apply | N/A | LOW | No opportunity |
| Juluca DTG + rilpivirine |
HIV-1 suppressed patients (2-drug switch) | ~£500m | ~2028–2031 | Both components are P-gp/BCRP substrates. Rilpivirine in particular has documented P-gp mediated brain efflux | Dual-substrate combination makes Juluca a theoretically attractive target — elacridar could boost both components' CNS penetration simultaneously. However, Juluca is losing market share to Dovato/Cabenuva and nearing LOE | EFFICACY ↑ | LOW | £300–400m (declining trajectory) |
| Zejula ★ niraparib |
Oncology — PARP1/2 inhibitor; ovarian cancer, GBM (investigational) | ~£630m | ~2031–2033 | YES — Confirmed. ABCB1 (P-gp) and ABCG2 (BCRP) both limit niraparib brain penetration. Published molecular pharmacology studies demonstrate that elacridar co-administration in WT mice increased niraparib brain concentration to levels seen in transporter knockout animals — complete normalisation. Elacridar reduced intestinal content recovery, confirming dual BBB + oral bioavailability enhancement | LEAD OPPORTUNITY. GSK has an ongoing Phase II trial (NCT) of niraparib in newly diagnosed glioblastoma. GBM is uniformly fatal (median OS ~15 months). Temozolomide is the current standard of care. Niraparib + elacridar combination addresses the primary pharmacological barrier limiting PARP inhibitor efficacy in GBM. Elacridar also re-sensitises P-gp/BCRP-overexpressing tumour cells that have become resistant. The combination could: (1) enable GBM indication approval with efficacy not achievable by niraparib alone, (2) extend niraparib's relevance post-ovarian-cancer LOE into a new blockbuster indication | BOTH | HIGH | £1,500–2,200m (GBM: ~100,000 cases/yr globally; unmet need commands high pricing; ~$200k/yr therapy) |
| Jemperli dostarlimab |
Oncology — anti-PD-1; endometrial cancer, dMMR solid tumours | ~£520m (est. full year) | ~2034+ | PD-1 monoclonal antibody — large molecule. P-gp/BCRP efflux is not clinically relevant for mAbs (molecular weight too high for efflux pump substrates) | No pharmacological rationale. Monoclonal antibodies are not P-gp substrates. Elacridar combination would add no benefit for Jemperli | N/A | LOW | No opportunity |
| Ojjaara / Omjjara momelotinib |
Oncology — JAK1/2 + ACVR1; myelofibrosis | ~£390m (est. full year 2024) | ~2033+ | JAK inhibitors are generally P-gp substrates (class effect demonstrated for ruxolitinib). Momelotinib-specific transporter data limited, but structural class and MW suggest P-gp/BCRP involvement likely | Myelofibrosis is a peripheral haematological malignancy — CNS penetration not the primary therapeutic concern. However, P-gp overexpression in resistant myelofibrosis clones could represent a resistance mechanism. Oral bioavailability improvement is a potential secondary benefit. Lower priority than GBM oncology opportunities | EFFICACY ↑ | LOW | £400–500m (marginal uplift; resistance reversal niche) |
| Blenrep belantamab mafodotin |
Oncology — anti-BCMA ADC; multiple myeloma (re-launched 2024) | <£50m (re-launch phase) | ~2034+ | ADC — the mafodotin payload (MMAF, auristatin derivative) is a known P-gp substrate. ADC components can be subject to P-gp efflux once internalised/released intracellularly | Interesting mechanistic angle: elacridar could inhibit intracellular P-gp efflux of MMAF payload in drug-resistant myeloma cells, re-sensitising tumours that have upregulated P-gp as a resistance mechanism. However, ADC biology is complex — effect on internalisation kinetics uncertain. Early-stage exploratory only | SAFETY ↑ | LOW | £100–200m (resistance reversal niche, if data supportive) |
| GSK5764227 risvutatug rezetecan |
Pipeline — B7-H3 ADC; ES-SCLC, osteosarcoma (Phase II/III) | Pre-revenue | N/A (pipeline) | ADC with novel payload — same mechanistic consideration as Blenrep re: intracellular P-gp efflux of cytotoxic payload | Osteosarcoma has a known MDR/P-gp resistance problem. Elacridar combination exploratory. SCLC also has very limited therapeutic options. Speculative but scientifically plausible. Would require early combination work in parallel with main development | EFFICACY ↑ | LOW | £200–400m (if resistance reversal data supportive) |
| Nucala mepolizumab |
Resp/Immunology — anti-IL-5 mAb; severe asthma, COPD, EGPA, HES | ~£1,800m | ~2030+ | Monoclonal antibody — not a P-gp/BCRP substrate. No efflux mechanism relevant | No pharmacological rationale. Biologics are not P-gp substrates | N/A | LOW | No opportunity |
| Benlysta belimumab |
Immunology — anti-BLys mAb; systemic lupus erythematosus | ~£1,450m | ~2028+ | Monoclonal antibody — no P-gp relevance | No pharmacological rationale | N/A | LOW | No opportunity |
| Trelegy Ellipta FF/UMEC/VI — inhaled triple |
General Medicine — COPD & asthma (SITT) | ~£2,700m | ~2028–2030 | Inhaled delivery bypasses GI absorption / P-gp intestinal efflux. Local lung pharmacology not meaningfully altered by systemic P-gp inhibition | No meaningful rationale. Inhaled steroids and bronchodilators act locally; P-gp inhibition at systemic level does not enhance pulmonary drug delivery | N/A | LOW | No opportunity |
| Seretide / Advair salmeterol / fluticasone |
General Medicine — COPD & asthma (legacy) | ~£1,000m | Genericised | Inhaled route — same limitation as Trelegy | No rationale. Already genericised; no commercial opportunity | N/A | LOW | No opportunity |
| Depemokimab GSK3511294 |
Pipeline — ultra-long-acting anti-IL-5; severe asthma, CRSwNP (regulatory review) | Pre-revenue | N/A (pipeline) | mAb — not a P-gp substrate | No rationale | N/A | LOW | No opportunity |
| Blujepa / Gepotidacin GSK2140944 |
Pipeline — bacterial type IIA topoisomerase inhibitor; uncomplicated UTI, gonorrhoea | Pre-revenue (2025 launch) | ~2035+ | Novel bacterial topoisomerase inhibitor — small molecule. P-gp substrate status under investigation. If P-gp efflux confirmed, elacridar could enhance tissue penetration in difficult-to-treat infections | Speculative. Antibiotics reaching urinary epithelium may benefit marginally from P-gp inhibition, but UTI drugs already achieve high urine concentrations. Low priority unless resistance / tissue penetration data emerge | EFFICACY ↑ | LOW | £100–200m (marginal; competitive antibiotic market) |
| Bepirovirsen GSK3228836 |
Pipeline — antisense oligonucleotide; chronic HBV | Pre-revenue (Phase III) | N/A | ASO — not a classical P-gp substrate. Hepatic delivery via GalNAc targeting | No meaningful rationale. ASOs have distinct PK not governed by ABC transporters | N/A | LOW | No opportunity |
| Latozinemab GSK4527223 |
Pipeline — anti-sortilin mAb; frontotemporal dementia (Phase II) | Pre-revenue | N/A | mAb — not a P-gp substrate. However, CNS penetration for large molecules is always limited by BBB | Biologic — not a P-gp substrate. Elacridar mechanism does not enhance mAb CNS penetration (mAbs cross BBB via transcytosis, not passive diffusion subject to P-gp). No opportunity | N/A | LOW | No opportunity |
| Camlipixant GSK5464714 |
Pipeline — P2X3 antagonist; refractory chronic cough (Phase III) | Pre-revenue | N/A | Small molecule P2X3 antagonist — transporter substrate status unknown. P2X3 receptors are peripheral (vagal afferents); some CNS expression | If camlipixant has meaningful P-gp efflux, elacridar co-administration could enhance CNS P2X3 blockade (relevant for central sensitisation in cough). Exploratory hypothesis only — no published transporter data | EFFICACY ↑ | LOW | £150–300m (speculative; cough market sizeable but competitive) |
| Linerixibat GSK2330672 |
Pipeline — IBAT inhibitor; cholestatic pruritus in PBC (NDA/MAA submitted) | Pre-revenue | N/A | IBAT inhibitor designed to act luminally in the gut — systemic P-gp inhibition would not be beneficial and could increase unwanted systemic absorption | Counter-indicated: elacridar would increase systemic exposure of a drug deliberately designed for minimal systemic absorption. Avoid | N/A | LOW | No opportunity (potentially harmful) |
| Shingrix recombinant zoster vaccine |
Vaccines — herpes zoster prevention | £3,176m | N/A (vaccine) | Vaccine adjuvant (AS01B) — not a P-gp substrate. Immunological mechanism | No rationale. Vaccine immunogenicity is not governed by drug efflux transporters | N/A | LOW | No opportunity |
| Arexvy RSV vaccine |
Vaccines — RSV prevention in adults 50+ | ~£900m (declining) | N/A (vaccine) | Not applicable — vaccine | No rationale | N/A | LOW | No opportunity |
LEAD PROGRAMME · ONCOLOGY · CNS · PARP INHIBITION + P-gp/BCRP BLOCKADE
The pharmacology is ironclad. Published peer-reviewed studies (Martins et al., ACS Molecular Pharmaceutics, 2021) demonstrate unequivocally that niraparib is a dual P-gp and BCRP substrate, and that elacridar co-administration in wild-type mice completely normalises brain concentrations to levels seen in ABCB1/ABCG2 double-knockout animals. This is not a theoretical interaction — it is published, reproducible pharmacology. The brain-to-plasma ratio increases dramatically without meaningful change in systemic plasma exposure, meaning the benefit is targeted to the CNS compartment where GBM resides.
GSK is already in the space. Niraparib is under investigation for glioblastoma — GSK has internally validated the hypothesis that PARP inhibition could add to GBM treatment. The missing piece is adequate CNS drug exposure, which elacridar directly solves. Our combination enters a development narrative that is already partly built. We are not asking GSK to pivot; we are showing them the key they didn't know they were missing.
The indication has the highest unmet need in oncology. GBM is uniformly fatal, with no meaningful therapeutic advances in 20 years. FDA and EMA grant accelerated pathways. Breakthrough Therapy Designation is highly probable for a combination showing meaningfully improved GBM survival. The willingness-to-pay in GBM is among the highest in oncology — US pricing for a GBM treatment is routinely $150,000–$250,000/year.
Elacridar also reverses tumour-level resistance. Beyond the BBB, GBM cells upregulate P-gp and BCRP as resistance mechanisms. The combination therefore has a dual benefit: (1) better initial CNS penetration achieving therapeutic concentrations, and (2) re-sensitisation of treatment-resistant tumour cells that have upregulated efflux. This dual mechanism is the combination's most commercially defensible story.
The safety profile is favourable. In Phase I clinical trials, elacridar was demonstrated to be safe with mild side effects when combined with doxorubicin. In combination with oral topotecan, elacridar more than doubled oral bioavailability safely. In GBM, where the alternative is death within 15 months, the safety bar is appropriately contextualised. A well-formulated oral bioavailable elacridar product, titrated to achieve selective BBB transporter saturation, has a manageable safety profile with primarily haematological monitoring required.
The combination creates a new patent lifecycle. A fixed-dose combination product (niraparib + bioavailable elacridar) in GBM would carry composition-of-matter patent protection and method-of-use patents extending well beyond niraparib's 2031–33 LOE, creating a decade+ protected franchise in a high-value indication.
An estimated 15–50% of people living with HIV on suppressive ART develop some degree of neurocognitive impairment (HAND) — driven by persistent low-level CNS viral replication in the HIV CNS reservoir. Dolutegravir (in Dovato) is a P-gp substrate with confirmed limited BBB penetration. Elacridar co-dosing in published preclinical models has been shown to enhance antiretroviral CNS exposure meaningfully. A Dovato + elacridar triple combination targeting HAND could command a substantial premium in the £2.2bn Dovato franchise, creating a neuro-HIV subspecialty. LOE not until 2031 provides sufficient runway. This is a niche-within-a-blockbuster strategy: even capturing 15% of Dovato patients at a premium price generates £400–500m incremental revenue.
Projected incremental sales: £400–600m at peak · LOE: 2033+ (new combination patent)
Platinum-resistant ovarian cancer patients frequently demonstrate P-gp overexpression as a resistance mechanism. While niraparib is used in platinum-sensitive ovarian cancer, an elacridar combination specifically targeting P-gp-overexpressing platinum-resistant tumours represents a clearly differentiated population. Published in vitro data show elacridar restores niraparib sensitivity in resistant cell models. This creates a companion diagnostic opportunity (P-gp expression by IHC or mRNA), which is both scientifically compelling and commercially strategic — selecting enriched responders to demonstrate a clean Phase II signal. Estimated ~70,000 platinum-resistant OC patients in developed markets annually represent a substantial opportunity.
Projected incremental sales: £300–500m at peak · Companion diagnostic required
| Priority | Combination | Indication | Mechanism | Current Drug Sales | Projected Combo Peak | LOE of Parent Drug | Development Stage |
|---|---|---|---|---|---|---|---|
| ★ 1 — LEAD | Niraparib + Elacridar | Newly diagnosed Glioblastoma (GBM) | BBB penetration + MDR reversal | £630m | £1,500–2,200m | 2031–33 | GSK Phase II (niraparib alone); elacridar combination ready for Phase Ib |
| 2 | Dovato + Elacridar | HIV-Associated Neurocognitive Disorders (HAND) | Enhanced CNS reservoir penetration of DTG | £2,239m | £400–600m incremental | 2031 | Preclinical — ready for Phase I/II proof-of-concept |
| 3 | Niraparib + Elacridar | P-gp+ Platinum-resistant Ovarian Cancer | MDR reversal in resistant tumours; companion dx required | £630m (shared) | £300–500m | 2031–33 | In vitro data; Phase II design ready |
| 4 | Ojjaara/Omjjara + Elacridar | JAK-inhibitor resistant Myelofibrosis | P-gp-mediated resistance reversal in refractory MF | ~£390m | £100–200m incremental | ~2033 | Preclinical hypothesis; low priority |
| 5 | Blenrep + Elacridar | P-gp-overexpressing Relapsed/Refractory Multiple Myeloma | Intracellular MMAF payload efflux reversal | <£50m | £100–200m | ~2034 | Exploratory in vitro concept only |